Sugi Predict

Sugi Predict / Compounds / SCHEMBL3124589

SCHEMBL3124589

SCHEMBL3124589

COc1ccc2[nH]c(=O)[nH]c(=O)c2c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 0.63
▸ KDM4E B2RXH2 7/20 0.63
▸ HSD17B10 Q99714 3/20 0.63
▸ MEN1 O00255 2/20 0.63
▸ MAPT P10636 2/20 0.63
▸ KMT2A Q03164 2/20 0.63
▸ TSHR P16473 1/20 0.63
▸ GFER P55789 1/20 0.63
▸ HPGD P15428 6/20 0.59
▸ SMN1; SMN2 Q16637 3/20 0.59
▸ ABCG2 Q9UNQ0 1/20 0.57
▸ DYRK1A Q13627 2/20 0.55
▸ NPC1 O15118 2/20 0.54
▸ RAB9A P51151 2/20 0.54
▸ POLB P06746 1/20 0.53
▸ GAA P10253 1/20 0.53
▸ TDP1 Q9NUW8 1/20 0.53
▸ L3MBTL1 Q9Y468 1/20 0.53
▸ PDGFRB P09619 1/20 0.53
▸ LMNA P02545 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31275105 0.86 KDM4E (0.60) ALDH1A1KDM4EHSD17B10MEN1MAPT
SCHEMBL7028805 0.86 KDM4E (0.60) ALDH1A1KDM4EHSD17B10MEN1MAPT
SCHEMBL3792832 0.81 PARP15 (0.54) ALDH1A1KDM4EHSD17B10MEN1MAPT
SCHEMBL7029183 0.81 KIF11 (0.50) ALDH1A1KDM4EHSD17B10MEN1MAPT
SCHEMBL7032301 0.81 HSD17B10 (0.61) ALDH1A1KDM4EHSD17B10MEN1MAPT
SCHEMBL21681287 0.81 PARP1 (0.56) ALDH1A1KDM4EHSD17B10MEN1MAPT
SCHEMBL30076444 0.81 HSD17B10 (0.66) ALDH1A1KDM4EHSD17B10MEN1MAPT
SCHEMBL2107333 0.81 HSD17B10 (0.66) ALDH1A1KDM4EHSD17B10MEN1MAPT
SCHEMBL7024662 0.80 PDE3B (0.53) ALDH1A1KDM4EHPGDSMN1; SMN2POLB
SCHEMBL12285521 0.79 ABCG2 (0.83) ALDH1A1KDM4EHSD17B10MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1608317-A4 DIPEPTIDYL PEPTIDASE INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2006-12-27 — — EP claimed
EP-1608317-A2 DIPEPTIDYL PEPTIDASE INHIBITORS Takeda San Diego, Inc. (US) 2005-12-28 — — EP claimed
US-20050004117-A1 Dipeptidyl peptidase inhibitors SYRRX, INC. 2005-01-06 — — US claimed
WO-2004087053-A9 DIPEPTIDYL PEPTIDASE INHIBITORS SYRRX INC (US) 2004-11-11 — — WO claimed
WO-2004087053-A2 DIPEPTIDYL PEPTIDASE INHIBITORS SYRRX, INC. (US) 2004-10-14 — — WO claimed
US-20250084060-A1 PRMT5 INHIBITORS AND METHODS OF TREATMENT HANGZHOU UNOGEN BIOTECH, LTD. (CN) 2025-03-13 — — US disclosed
EP-3960735-B1 QUINAZOLINE DERIVATIVES USED TO TREAT HIV GILEAD SCIENCES INC (US) 2023-09-13 — — EP disclosed
US-11447493-B2 Inhibitors of cyclin-dependent kinases KINNATE BIOPHARMA INC. 2022-09-20 — — US disclosed
EP-3787629-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES Kinnate Biopharma Inc. (US) 2021-03-10 — — EP disclosed
US-20210053969-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES KINNATE BIOPHARMA INC. 2021-02-25 — — US disclosed
US-20210053969-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES KINNATE BIOPHARMA INC. 2021-02-25 — — US disclosed
WO-2020063854-A1 QUINOLINE-BASED DERIVATIVES AS VAP-1 INHIBITORS 南京明德新药研发有限公司 2020-04-02 — — WO disclosed
WO-2004087053-A2 DIPEPTIDYL PEPTIDASE INHIBITORS SYRRX, INC. (US) 2004-10-14 — — WO disclosed
WO-2003055866-A1 QUINAZOLINE AND QUINOLINE DERIVATIVE COMPOUNDS AS INHIBITORS OF PROLYLPEPTIDASE, INDUCERS OF APOPTOSIS AND CANCER TREATMENT AGENTS BAYER PHARMACEUTICALS CORPORATION (US) 2003-07-10 — — WO disclosed
EP-0878468-B1 Process for producing 1-substituted tetrahydroquinazolines SUMITOMO CHEMICAL CO (JP) 2003-03-19 — — EP disclosed
EP-0775697-B1 Process for producing 1-substituted tetrahydroquinazolindionen SUMITOMO CHEMICAL CO (JP) 2003-02-12 — — EP disclosed
US-5994542-A Process for producing 1-substituted tetrahydroquinazolines SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1999-11-30 — — US disclosed
EP-0878468-A1 Process for producing 1-substituted tetrahydroquinazolines SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1998-11-18 — — EP disclosed
US-5756738-A Process for producing 1-substituted tetrahydroquinazolines SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1998-05-26 — — US disclosed
EP-0775697-A1 Process for producing 1-substituted tetrahydroquinazolindionen SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1997-05-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004117-A1 Dipeptidyl peptidase inhibitors DPP9, DPP4, DPP3 ALDH1A1 816/4885KDM4E 2328/4885HSD17B10 1128/4885
US-20210053969-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES CDK2, CCNK, CDK1 ALDH1A1 3722/4885KDM4E 1278/4885HSD17B10 2436/4885
US-11447493-B2 Inhibitors of cyclin-dependent kinases CDK2, CCNK, CDK1 ALDH1A1 3722/4885KDM4E 1278/4885HSD17B10 2436/4885
US-20250084060-A1 PRMT5 INHIBITORS AND METHODS OF TREATMENT PRMT5, PRMT3, PRMT1 ALDH1A1 4294/4885KDM4E 54/4885HSD17B10 4002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.